172 related articles for article (PubMed ID: 37684548)
1. Factors associated with adherence to medications for lowering breast cancer risk between female Medicare beneficiaries in Alabama and nationwide.
Qian J; Truong B; Tanni KA
Cancer Causes Control; 2024 Feb; 35(2):215-222. PubMed ID: 37684548
[TBL] [Abstract][Full Text] [Related]
2. Endocrine therapy use among elderly hormone receptor-positive breast cancer patients enrolled in Medicare Part D.
Riley GF; Warren JL; Harlan LC; Blackwell SA
Medicare Medicaid Res Rev; 2011 Dec; 1(4):. PubMed ID: 22340780
[TBL] [Abstract][Full Text] [Related]
3. Risk-reducing medications for primary breast cancer: a network meta-analysis.
Mocellin S; Goodwin A; Pasquali S
Cochrane Database Syst Rev; 2019 Apr; 4(4):CD012191. PubMed ID: 31032883
[TBL] [Abstract][Full Text] [Related]
4. The introduction of generic aromatase inhibitors and treatment adherence among Medicare D enrollees.
Neuner JM; Kamaraju S; Charlson JA; Wozniak EM; Smith EC; Biggers A; Smallwood AJ; Laud PW; Pezzin LE
J Natl Cancer Inst; 2015 Aug; 107(8):. PubMed ID: 25971298
[TBL] [Abstract][Full Text] [Related]
5. Treatment utilization patterns of newly initiated oral anticancer agents in a national sample of Medicare beneficiaries.
Doshi JA; Jahnke J; Raman S; Puckett JT; Brown VT; Ward MA; Li P; Manz CR
J Manag Care Spec Pharm; 2021 Oct; 27(10):1457-1468. PubMed ID: 34595957
[No Abstract] [Full Text] [Related]
6. Socio-demographic and geographic variations in the utilization of hormone therapy in older women with breast cancer after Medicare Part-D coverage.
Wang X; Du XL
Med Oncol; 2015 May; 32(5):154. PubMed ID: 25837434
[TBL] [Abstract][Full Text] [Related]
7. Examining the Effect of Medication Adherence on Risk of Subsequent Fracture Among Women with a Fragility Fracture in the U.S. Medicare Population.
Keshishian A; Boytsov N; Burge R; Krohn K; Lombard L; Zhang X; Xie L; Baser O
J Manag Care Spec Pharm; 2017 Nov; 23(11):1178-1190. PubMed ID: 29083977
[TBL] [Abstract][Full Text] [Related]
8. Association between dispensing channel and medication adherence among medicare beneficiaries taking medications to treat diabetes, high blood pressure, or high blood cholesterol.
Iyengar RN; Balagere DS; Henderson RR; LeFrancois AL; Rabbitt RM; Frazee SG
J Manag Care Spec Pharm; 2014 Aug; 20(8):851-61. PubMed ID: 25062079
[TBL] [Abstract][Full Text] [Related]
9. Medication Use for the Risk Reduction of Primary Breast Cancer in Women: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
Nelson HD; Fu R; Zakher B; Pappas M; McDonagh M
JAMA; 2019 Sep; 322(9):868-886. PubMed ID: 31479143
[TBL] [Abstract][Full Text] [Related]
10. Predictors of Nonadherence to Topical Intraocular Pressure Reduction Medications Among Medicare Members: A Claims-Based Retrospective Cohort Study.
Sheer R; Bunniran S; Uribe C; Fiscella RG; Patel VD; Chandwani HS
J Manag Care Spec Pharm; 2016 Jul; 22(7):808-817a. PubMed ID: 27348282
[TBL] [Abstract][Full Text] [Related]
11. The impact of the introduction of generic aromatase inhibitors on adherence to hormonal therapy over the full course of 5-year treatment for breast cancer.
Ma S; Shepard DS; Ritter GA; Martell RE; Thomas CP
Cancer; 2020 Aug; 126(15):3417-3425. PubMed ID: 32484941
[TBL] [Abstract][Full Text] [Related]
12. Adherence to Adjuvant Endocrine Therapy and Survival Among Older Women with Early-Stage Hormone Receptor-Positive Breast Cancer.
Park C; Heo JH; Mehta S; Han S; Spencer JC
Clin Drug Investig; 2023 Mar; 43(3):167-176. PubMed ID: 36740664
[TBL] [Abstract][Full Text] [Related]
13. Phase 3 trials of aromatase inhibitors for breast cancer prevention: following in the path of the selective estrogen receptor modulators.
Dunn BK; Ryan A
Ann N Y Acad Sci; 2009 Feb; 1155():141-61. PubMed ID: 19250201
[TBL] [Abstract][Full Text] [Related]
14. Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?
Howell A; Howell SJ; Clarke R; Anderson E
J Steroid Biochem Mol Biol; 2001 Dec; 79(1-5):227-37. PubMed ID: 11850229
[TBL] [Abstract][Full Text] [Related]
15. Medication Use to Reduce Risk of Breast Cancer: US Preventive Services Task Force Recommendation Statement.
; Owens DK; Davidson KW; Krist AH; Barry MJ; Cabana M; Caughey AB; Doubeni CA; Epling JW; Kubik M; Landefeld CS; Mangione CM; Pbert L; Silverstein M; Tseng CW; Wong JB
JAMA; 2019 Sep; 322(9):857-867. PubMed ID: 31479144
[TBL] [Abstract][Full Text] [Related]
16. Medication Nonadherence Among Medicare Beneficiaries with Comorbid Chronic Conditions: Influence of Pharmacy Dispensing Channel.
Iyengar RN; LeFrancois AL; Henderson RR; Rabbitt RM
J Manag Care Spec Pharm; 2016 May; 22(5):550-60. PubMed ID: 27123916
[TBL] [Abstract][Full Text] [Related]
17. Association of teriparatide adherence and persistence with clinical and economic outcomes in Medicare Part D recipients: a retrospective cohort study.
Hazel-Fernandez L; Louder AM; Foster SA; Uribe CL; Burge RT
BMC Musculoskelet Disord; 2013 Jan; 14():4. PubMed ID: 23281846
[TBL] [Abstract][Full Text] [Related]
18. Assessing the association between medication adherence, as defined in quality measures, and disease-state control, health care utilization, and costs in a retrospective database analysis of Medicare supplemental beneficiaries using statin medications.
Axon DR; Vaffis S; Chinthammit C; Lott BE; Taylor AM; Pickering M; Black H; Warholak T; Campbell PJ
J Manag Care Spec Pharm; 2020 Dec; 26(12):1529-1537. PubMed ID: 33251989
[No Abstract] [Full Text] [Related]
19. Risk of Nondherence to Diabetes Medications Among Medicare Advantage Enrollees: Development of a Validated Risk Prediction Tool.
Mhatre SK; Serna O; Sansgiry S; Fleming ML; Essien EJ; Sansgiry SS
J Manag Care Spec Pharm; 2016 Nov; 22(11):1293-1301. PubMed ID: 27783546
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]